Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Hoff

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Haematologica|January 13, 2022
Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children's Oncology Group studyFieke W Hoff, Anneke D Van Dijk, Yihua Qiu, et al.
Science Translational Medicine|April 10, 2020
The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viabilitySara Mirali, Aaron Botham, Veronique Voisin, et al.
Nature Cell Biology|June 6, 2022
The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemnessGeethu Emily Thomas, Grace Egan, Laura García-Prat, et al.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Cancer Journal|April 3, 2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trialFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
Nature Communications|May 19, 2022
Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemiaNatalia Baran, Alessia Lodi, Yogesh Dhungana, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Haematologica|January 13, 2022
Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children's Oncology Group studyFieke W Hoff, Anneke D Van Dijk, Yihua Qiu, et al.
Science Translational Medicine|April 10, 2020
The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viabilitySara Mirali, Aaron Botham, Veronique Voisin, et al.
Nature Cell Biology|June 6, 2022
The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemnessGeethu Emily Thomas, Grace Egan, Laura García-Prat, et al.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Cancer Journal|April 3, 2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trialFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
Nature Communications|May 19, 2022
Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemiaNatalia Baran, Alessia Lodi, Yogesh Dhungana, et al.
Pageof 9